What Soligenix, Inc. does.

This Annual Report on Form 10-K contains statements of a forward-looking nature relating to future events or our future financial performance. These statements are only predictions and actual events or results may differ materially. In evaluating such statements, you should carefully consider the various factors identified in this report that could cause actual results to differ materially from those indicated in any forward-looking statements, including those set forth in “Risk Factors” in this Annual Report on Form 10-K. See “Cautionary Note Regarding Forward Looking Statements.”

We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.

Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy (“PDT”), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the first Phase 3 FLASH ( F luorescent L ight A ctivated S ynthetic H ypericin) study and agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, we began patient enrollment during December 2024 for the second Phase 3 study called “FLASH2” ( F luorescent L ight A ctivated S ynthetic H ypericin 2). We anticipate top-line results in the second half of 2026. Upon successful completion of the Phase 3 FLASH2 study, regulatory approval will be sought to support potential commercialization worldwide.

Revenue and profit, by fiscal year.

More on SNGX.

• Soligenix, Inc. summary
• Soligenix, Inc. financial statements
• Soligenix, Inc. key metrics
• Soligenix, Inc. health scores and style box
• Soligenix, Inc. earnings
• Soligenix, Inc. dividends
• Soligenix, Inc. valuation
• Soligenix, Inc. ownership and insiders
• Soligenix, Inc. peers

Figures from Soligenix, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.